Gate Neurosciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $25M

  • Investors
  • 7

Gate Neurosciences General Information

Description

Developer of neuronal therapeutics designed to treat central neurologic and psychiatric disorders. The company's therapies are designed to function by enhancing neuroplasticity, strengthening neuronal connections, and rebalancing signaling to restore healthy brain function that addresses underlying disease pathophysiology, enabling patients and doctors to have a proper way to treat central nervous system conditions by creating safe, potent, and rapid-acting therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1210 Waterway Boulevard
  • Indianapolis, IN 46202
  • United States
Primary Industry
Other Healthcare Services
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 1210 Waterway Boulevard
  • Indianapolis, IN 46202
  • United States

Gate Neurosciences Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gate Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 05-Oct-2022 $25M Completed Pre-Clinical Trials
4. Early Stage VC 09-Dec-2021 Completed Pre-Clinical Trials
3. Seed Round 29-Mar-2021 Completed Pre-Clinical Trials
2. Seed Round 11-Jun-2019 $4.5M $4.5M Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2018 Completed
To view Gate Neurosciences’s complete valuation and funding history, request access »

Gate Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Gate Neurosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Gate Neurosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gate Neurosciences Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Innoviva Corporation Minority
Luson BioVentures Venture Capital Minority
Thornapple River Capital Venture Capital Minority
Evolution VC Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Gate Neurosciences FAQs

  • When was Gate Neurosciences founded?

    Gate Neurosciences was founded in 2018.

  • Where is Gate Neurosciences headquartered?

    Gate Neurosciences is headquartered in Indianapolis, IN.

  • What is the size of Gate Neurosciences?

    Gate Neurosciences has 13 total employees.

  • What industry is Gate Neurosciences in?

    Gate Neurosciences’s primary industry is Other Healthcare Services.

  • Is Gate Neurosciences a private or public company?

    Gate Neurosciences is a Private company.

  • What is Gate Neurosciences’s current revenue?

    The current revenue for Gate Neurosciences is .

  • How much funding has Gate Neurosciences raised over time?

    Gate Neurosciences has raised $45.6M.

  • Who are Gate Neurosciences’s investors?

    AbbVie Ventures, Innoviva, Luson BioVentures, Thornapple River Capital, and Evolution VC Partners are 5 of 7 investors who have invested in Gate Neurosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »